ArticleHeliyon2022
Antimalarial activity of the hydroalcoholic crude extract and solvent fractions of
Article in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Antiplasmodial Screening of Phikud Navakot Formulation and In Vivo Evaluation, Toxicity, and Phytochemical Profiling of the PotentScientifica · 2025Article
- Antinociceptive and antiinflammatory activities of crude leave extract and solvent fractions ofFrontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ethnopharmacological relevance: In Ethiopia, the indigenous medicinal plant Aim of the study: In this work, the antiplasmodial activity of Materials and methods: 80% methanol was used to extract the leaves of Results: All of the tested crude extracts were safe at a dose of 2000 mg/kg. At 400 mg/kg dose both the 80% methanol extract and chloroform fraction exhibited antimalarial activity with parasitemia suppression values of 86.31%, and 76.56% in the four-day suppressive test, 81.97% and 72.05% in Rane's test, and 69.05% and 62.88% in the prophylactic test, respectively. Conclusion: Collectively, the oral dose of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.